One principal physical delay stage.
The delayed-release capsule can provide the outer delayed-release element. The format name alone does not establish a second coated-particle stage.
Delayed-release outer capsule
Enzyme-containing material inside
Bilamex™ Dual-Phase Delivery Technology
Delayed Release Is Only the First Stage.
Bilamex™ combines a delayed-release capsule with coated enzyme-containing particles—a two-stage physical delivery architecture that does not rely on the outer capsule alone.
Architecture describes how the dosage form is built. Finished-product testing separately documents how a tested lot behaved under the stated method.
Inside Bilamex™2 physical stages
1 · Delayed-release capsuleOuter dosage-form stage.
→
2 · Coated particlesSecond physical stage around enzyme-containing material.
Beyond Capsule-Only Delayed Release
Delayed release is one layer. Bilamex™ is a defined two-stage system.
The distinction is structural: a capsule-only delayed-release format relies on the outer capsule as its principal physical delay stage. Bilamex™ adds coated enzyme-containing particles inside the capsule.
Two disclosed physical stages.
Bilamex™ retains the delayed-release capsule and adds a second physical stage around the enzyme-containing material.
Stage 1 · Delayed-release capsule
Stage 2 · Coated enzyme-containing particles
Scope of the comparison: this describes physical architecture. It does not by itself establish superior absorption, bioavailability, or clinical outcomes, and individual products can use different constructions.
Why Gastric Protection Matters
Acid vulnerability is the formulation problem. Bilamex™ is the architecture response.
Published research shows that serratiopeptidase activity is pH-dependent and can be substantially reduced under acidic conditions. Bilamex™ addresses that formulation problem with two disclosed physical protection stages, while finished-product testing and lot traceability separately document the iSerra dosage form.
2005 Formulation Study · Visualized
What acidic medium did to proteolytic activity in this formulation model.
85.3%
Reported activity loss
Document the acid vulnerability.
The 2005 study demonstrates that acidic exposure can materially reduce serratiopeptidase proteolytic activity in a formulation model. That establishes the problem to solve without claiming a universal loss percentage.
Use two physical protection stages.
Stage 1: delayed-release outer capsule.
Stage 2: coated enzyme-containing particles inside. The second stage is a disclosed physical layer rather than an inference from “delayed release” alone.
Test gastric-phase behavior separately.
Reference Lot 6798 showed no disintegration through the 60-minute gastric phase under USP <2040>, followed by complete disintegration at 37 minutes in the intestinal phase.
Trace the evidence to the bottle lot.
The production lot on the bottle is the lookup key for the applicable available verification record, helping keep lot-specific results separate from broad product claims.
2024 · The FEBS Journal
Purified, calcium-refolded zymogenic serratiopeptidase retained more than 50% of original activity from pH 5 to 10, with maximal activity around pH 7.5—additional evidence that enzyme activity varies with pH. Study ↗
2026 · BBA Proteins and Proteomics
Recent structure-guided work describes reduced serratiopeptidase activity at extreme pH as a functional limitation and investigates an engineered variant with improved pH-dependent resilience. PubMed ↗
Evidence boundary: the published studies above establish pH sensitivity in their own enzyme or formulation models; they did not test Bilamex™. Bilamex™ describes iSerra’s physical delivery architecture. The USP <2040> observation below is separate finished-product disintegration evidence for reference Lot 6798 and is not an absorption, bioavailability, or clinical-effectiveness study.
Finished-Product Evidence · Reference Lot 6798
Architecture and testing answer different questions.
Bilamex™ describes how iSerra is built. USP <2040> finished-product disintegration testing separately documents how the tested finished dosage form behaved under the stated conditions.
60 minGastric phase
No disintegration through 60 minutes.
37 minIntestinal phase
Complete disintegration at 37 minutes.
These observations apply specifically to Lot 6798, tested August 5, 2026. They are not a clinical efficacy, absorption, or bioavailability study and should not be generalized to every lot.
Current shipping lot · 6798Tested 2026-08-05
Measured Activity292,327 SPU
Declared Specification≥ 250,000 SPU/capsule
DeliveryBilamex™ Dual-Phase
DisintegrationPass — USP <2040>
LaboratoryIndependent ISO 17025-accredited laboratory
Activity MethodUSP proteolytic assay
The current shipping lot is shown as a separate record. The static 60/37-minute observation above remains attributed only to reference Lot 6798.
Place Delivery in Context
Bilamex™ is one part of the iSerra evidence stack.
Activity, delivery, finished-product testing, and lot traceability each answer a different buying question.
250,000 SPU per capsule
See how activity, serving size, and ingredient weight are separated.
EXPLORE 250,000 SPU →Use the same four criteria
Compare activity, delivery architecture, finished-product testing, and traceability.
VIEW THE EVIDENCE GUIDE →Verify the bottle lot
Use the production lot on the bottle to access the applicable available record.
VERIFY A LOT →Questions Before Purchase
The distinctions worth keeping clear.
What makes Bilamex™ “dual phase”?
It identifies two physical stages: a delayed-release capsule and coated enzyme-containing particles inside it.
Does the architecture prove better absorption?
No. The architecture describes construction. The page does not present it as a clinical absorption or bioavailability result.
What do the 60- and 37-minute figures refer to?
They are Lot 6798 finished-dosage-form disintegration observations under USP <2040>, not a result that should be generalized to every lot.
How can I verify my bottle?
Use the production lot printed on the bottle at the Verify Your Lot page.
iSerra® Serrapeptase
Choose a defined delivery architecture with separate finished-product evidence.
250,000 SPU per capsule · Bilamex™ Dual-Phase Delivery · finished-product testing · Veriphase™ lot-specific verification.
$ 74.95
One-time 1-bottle starting option · 90 capsulesVIEW PRICING & PURCHASE OPTIONSPurchase page shows current one-time, subscription, and multi-bottle options.